Integrin αvβ3 Expression in Colon Carcinoma Correlates with Survival
Author(s) -
Alain Vonlaufen,
Guido Wiedle,
Bettina Borisch,
Stefan Birrer,
Peter Luder,
Beat A. Imhof
Publication year - 2001
Publication title -
modern pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.596
H-Index - 153
eISSN - 1530-0285
pISSN - 0893-3952
DOI - 10.1038/modpathol.3880447
Subject(s) - integrin , alpha (finance) , pathology , angiogenesis , beta (programming language) , immunohistochemistry , medicine , colorectal cancer , alpha v beta 3 , carcinoma , neovascularization , blood vessel , monoclonal antibody , cancer research , antibody , cancer , immunology , receptor , vitronectin , construct validity , programming language , nursing , computer science , patient satisfaction
Integrin alpha(v)beta(3) is expressed by newly formed blood vessels in diseased and neoplastic tissue and can therefore be used as a marker for angiogenesis. We investigated its expression on the vasculature of 40 colon carcinomas using the anti-alpha(v)beta(3)-specific monoclonal antibody LM609. The average relapse-free interval and overall survival in patients suffering from colon carcinomas with high vascular expression of alpha(v)beta(3) integrin was significantly reduced compared with that in patients with low alpha(v)beta(3) integrin expressing tumor vasculature. Moreover, the expression level of alpha(v)beta(3) integrin correlated with the presence of liver metastases. In conclusion, we propose vascular expression of alpha(v)beta(3) integrin as a prognostic indicator for colon carcinoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom